Product Information
NAPROXEN 375 MG TABLET is a generic product labeled by Exelan Pharmaceuticals Inc., priced at $0.0588 per EA under NDC 76282034105. Its NADAC has been published 521 times since Oct 12, 2016.
FDA first approved this application on Aug 24, 2011.
Strength
375 mg/1
Manufacturer
Exelan Pharmaceuticals Inc.NDC
76282034105
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
NAPROXENApproval Type
Generic (ANDA)
FDA Application
ANDA091305FDA Approved
8/24/2011
On Market Since
6/10/2016
Pharmacological Classes
Price Statistics
The NADAC for NAPROXEN 375 MG TABLET has been published 521 times since Oct 12, 2016, and over the history we have for it it has risen 3.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0588 per EA |
|---|---|
| All-time high | $0.0808 (Jun 16, 2021) |
| All-time low | $0.0474 (Apr 17, 2024) |
| 52-week high | $0.0601 |
| 52-week low | $0.0561 |
| Median price | $0.0649 |
| Average price | $0.0661 |
| Largest weekly change | -28.8% (Apr 17, 2024) |
| Weeks tracked | 521 |
| Tracking since | Oct 12, 2016 |
Generic Alternatives
The matcher finds 10 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 3% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Exelan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Naproxen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NAPROXEN 375 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for NAPROXEN 375 MG TABLET, manufactured by Exelan Pharmaceuticals Inc., is $0.0588 per EA (NDC 76282034105), effective Sep 30, 2026.
How has the price of NAPROXEN 375 MG TABLET changed over time?
Over the history we have for it, the NADAC for NAPROXEN 375 MG TABLET has risen 3.3%. It has been tracked across 521 weekly CMS publications since Oct 12, 2016.
What are the highest and lowest recorded NADAC prices for NAPROXEN 375 MG TABLET?
Since Oct 12, 2016, the NADAC for NAPROXEN 375 MG TABLET has ranged from a low of $0.0474 (Apr 17, 2024) to a high of $0.0808 (Jun 16, 2021), with a median of $0.0649 per EA.
Are there cheaper alternatives to NAPROXEN 375 MG TABLET?
Yes. 10 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NAPROXEN 375 MG TABLET, is $0.0573 per EA — about 3% below NAPROXEN 375 MG TABLET.
Who manufactures NAPROXEN 375 MG TABLET?
NAPROXEN 375 MG TABLET (NDC 76282034105) is labeled by Exelan Pharmaceuticals Inc., and CMS classifies it as a generic product.